File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.2217/pgs.15.174
- Scopus: eid_2-s2.0-84956633350
- WOS: WOS:000368939100011
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment
Title | Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment |
---|---|
Authors | |
Keywords | PIK3R1 PI3K MAPK p85 mutation targeted therapy |
Issue Date | 2016 |
Citation | Pharmacogenomics, 2016, v. 17, n. 3, p. 297-307 How to Cite? |
Abstract | © 2016 Future Medicine Ltd. The regulatory subunit of PI3K, p85α (encoded by PIK3R1), binds, stabilizes and inhibits the PI3K p110 catalytic subunit. Functional characterization of PIK3R1 mutations has identified not only hypomorphs with reduced inhibition of p110, but also hypomorphs and dominant negative mutants that disrupt a novel regulatory role of p85α on PTEN or neomorphs that activate unexpected signaling pathways. The diverse phenotypic spectrum of these PIK3R1 driver mutations underscores the need for different treatment strategies targeting tumors harboring these mutations. This article describes the functional consequences of the spectrum of PIK3R1 driver mutations and therapeutic liabilities they may engender. |
Persistent Identifier | http://hdl.handle.net/10722/225073 |
ISSN | 2023 Impact Factor: 1.9 2023 SCImago Journal Rankings: 0.439 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cheung, Lydia Wt | - |
dc.contributor.author | Mills, Gordon B. | - |
dc.date.accessioned | 2016-04-18T11:16:42Z | - |
dc.date.available | 2016-04-18T11:16:42Z | - |
dc.date.issued | 2016 | - |
dc.identifier.citation | Pharmacogenomics, 2016, v. 17, n. 3, p. 297-307 | - |
dc.identifier.issn | 1462-2416 | - |
dc.identifier.uri | http://hdl.handle.net/10722/225073 | - |
dc.description.abstract | © 2016 Future Medicine Ltd. The regulatory subunit of PI3K, p85α (encoded by PIK3R1), binds, stabilizes and inhibits the PI3K p110 catalytic subunit. Functional characterization of PIK3R1 mutations has identified not only hypomorphs with reduced inhibition of p110, but also hypomorphs and dominant negative mutants that disrupt a novel regulatory role of p85α on PTEN or neomorphs that activate unexpected signaling pathways. The diverse phenotypic spectrum of these PIK3R1 driver mutations underscores the need for different treatment strategies targeting tumors harboring these mutations. This article describes the functional consequences of the spectrum of PIK3R1 driver mutations and therapeutic liabilities they may engender. | - |
dc.language | eng | - |
dc.relation.ispartof | Pharmacogenomics | - |
dc.subject | PIK3R1 | - |
dc.subject | PI3K | - |
dc.subject | MAPK | - |
dc.subject | p85 | - |
dc.subject | mutation | - |
dc.subject | targeted therapy | - |
dc.title | Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.2217/pgs.15.174 | - |
dc.identifier.scopus | eid_2-s2.0-84956633350 | - |
dc.identifier.volume | 17 | - |
dc.identifier.issue | 3 | - |
dc.identifier.spage | 297 | - |
dc.identifier.epage | 307 | - |
dc.identifier.eissn | 1744-8042 | - |
dc.identifier.isi | WOS:000368939100011 | - |
dc.identifier.issnl | 1462-2416 | - |